Article Per Year (5 Year)
p-Index From 2021 - 2026
0
P-Index
This Author published in this journals
All Journal Indonesian Journal of Cancer The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy Jurnal Penyakit Dalam Indonesia
Aru W Sudoyo
Unknown Affiliation
Health Professions Medicine & Pharmacology

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
Chemotherapy and Targeting therapy in Colon Cancer SUDOYO, ARU W
Indonesian Journal of Cancer Vol 4, No 5 (2010): Workshops 2010
Publisher : "Dharmais" Cancer Center Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

https://www.scribd.com/doc/43602320/Chemotherapy-and-Targeting-therapy-in-Colon-Cancer
Chemotherapy for Advanced Colorectal Cancer among Indonesians in a Private Hospital in Jakarta: Survival when Best Treatment is Given Aru W Sudoyo; Ibrahim Basir; Levina Pakasi; Maureen Lukman
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy VOLUME 14, NUMBER 1, April 2013
Publisher : The Indonesian Society for Digestive Endoscopy

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (366.075 KB) | DOI: 10.24871/14120133-8

Abstract

Background: Survival of colorectal cancer in Indonesia is thought to be shorter due to to several factors, among these: ethnic, nutritional, and the low affordability factors. Aim of this study to assess and evaluate survival in advanced colorectal cancer when given the best drugs available as recommended by international guidelines.Method: A historical cohort study was done in patients with advanced colon or rectal cancer between 2008 and 2010 at Medistra Hospital. Cases were retrieved from medical record data. Subjects were included if they were diagnosed or had a relapse of their disease during the study period and were followed until they died or lost to follow-up. Staging procedure was done using the tumor node metastasis (TNM) system. All patients received the combination of 5-uorouracil (5-FU)/leucovorin (LV), oxaliplatin for 6 cycles (FOLFOX4) as the standard  rst-line regimen for metastatic colorectal cancer (mCRC) in Indonesia. Oral capecitabine and targeted therapy such as bevacizumab and cetuximab might were also given, whenever indicated.Results: Nineteen patients (48.7%) died during the study period, while the rest were alive or lost to follow-up. The median overall survival of patients was 18 months (95% CI = 6.98 – 29.02 months). The longest survival was76 months (the patient is still alive when this manuscript was being prepared). Patients with colon cancer tended to live longer than rectal cancer, i.e. 21 vs. 15 months; log-rank p = 0.147. There was no signi cant difference of survival between patients with stage IV disease and relapse cases, i.e. 18 vs. 12 months, log-rank p = 0.807. Conclusion: With proper treatment and access to cytostatics and biologicals, advanced colorectal cancer among Indonesian patients have the same survival rates as patients in more developed countries as reported in the literature. Keywords: advanced colorectal cancer, chemotherapy, survival
Hubungan Antibodi Anti Trombosit terhadap Respon Transfusi Trombosit pada Pasien Hemato-Onkologi yang Mendapatkan Multitransfusi Trombosit di RS Dr. Cipto Mangunkusomo Lubis, Anna Mira; Sudoyo, Aru W; Effendy, Shufrie; Djumhana, TB; Harimurti, Kuntjoro
Jurnal Penyakit Dalam Indonesia Vol. 2, No. 4
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Pendahuluan: Multitransfusi donor random dan paparan terhadap konsentrat trombosit yang termasuk non-leukocyte depleted diketahui sebagai faktor risiko terjadinya alloimunisasi (HLA dan HPA) yang dapat menjadi salah satu penyebab kegagalan transfusi. Oleh karena itu, perlu dilakukan penelitian mengenai hubungan antibodi anti trombosit tersebut dengan kegagalan respon transfusi trombosit pada pasien hemato-onkologi sehingga dapat dilakukan metode seleksi donor dan crossmatching trombosit donor dan resipien. Metode: Studi observasional dilakukan pada pasien hemato-onkologi dewasa yang mendapatkan multitransfusi trombosit di Rumah Sakit dr Cipto Mangunkusumo (RSCM) Jakarta. Pengamatan dilakukan pada respon transfusi dengan mengukur corrected count increment (CCI) 1 jam post transfusi dengan batas 7.500 m2/mL. Keadaan lain yang dapat mempengaruhi CCI dieksklusi dari penelitian. Antibodi (Ig G) dideteksi dari serum pre transfusi terhadap antigen HLA kelas 1, epitop GP IIb/ IIIa, Ib/IX dan Ia/IIa dengan teknik ELISA secara kualitatif. Pengukuran ini menggunakan kit ELISA komersial Pak-2 LE. Analisis statistik dilakukan dengan uji chi-square dan regresi logistik untuk ditentukan PR dengan IK 95%. Hasil: Selama periode Maret–Juni 2008 terkumpul 36 transfusi yang diberikan pada 21 pasien dengan berbagai diagnosis hemato-onkologi. Sebanyak 33,3% memberikan respon transfusi yang tidak memuaskan (CCI Simpulan: Pasien yang memiliki antibodi HLA kelas 1, memiliki kecenderungan kegagalan transfusi trombosit 11,4 kali lebih besar. Namun, hubungan antibodi GP IIb/IIIa dengan respon transfusi belum dapat ditentukan, sehingga dibutuhkan studi lanjutan dengan sampel yang lebih besar.
Co-Authors Abdulmuthalib Abdulmuthalib Agus Kosasih, Agus Andhika Rachman Anna Mira Lubis Ardian Saputra, Ardian Ary H Reksodiputro, Ary H Auda Aziz, Auda Cosphiadi Irawan Djumhana Atmakusumah, Djumhana Ibrahim Basir Idrus Alwi Kuntjoro Harimurti Levina Pakasi Linda Lison, Linda Lugyanti Sukrisman Lyana Lyana, Lyana Maureen Lukman Merry Wintery, Merry Nadia A Mulansari, Nadia A Rianto Setiabudy Shufrie Effendy Sri Inggriani, Sri TB Djumhana, TB Teguh Santoso